Markus Kaiser

Prof. Markus Kaiser


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2011 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
TCTim Clausen
Tim Clausen
MKMarkus Kaiser
Markus Kaiser
RHRobert Huber
Robert Huber
MEMichael Ehrmann
Michael Ehrmann

1 April 2008 in Nature
Verified
Journal Article
Closed access
MGMichael Groll
Michael Groll
BSBarbara Schellenberg
Barbara Schellenberg
ABAndre Bachmann
Andre Bachmann
CACrystal R. Archer
Crystal R. Archer
RHRobert Huber
Robert Huber
RDRobert Dudler
Robert Dudler

3 June 2022 in Cell
Verified
Journal Article
Open access
FMFrancesca E. Morreale
Francesca E. Morreale
SKStefan Kleine
Stefan Kleine
JLJulia Leodolter
Julia Leodolter
SJSabryna Junker
Sabryna Junker
DHDavid M. Hoi
David M. Hoi
TCTim Clausen
Tim Clausen
Hijacking the cellular protein degradation system offers unique opportunities for drug discovery, as exemplified by proteolysis-targeting chimeras. Despite their great promise for medical chemistry, so far, it has not been possible to reprogram the bacterial degradation machinery to interfere with microbial infections. Here, we develop small-molecule degraders, so-called BacPROTACs, that bind to the substrate receptor of the ClpC:ClpP protease, priming neo-substrates for degradation. In addition to their targeting function, BacPROTACs activate ClpC, transforming the resting unfoldase into its functional state. The induced higher-order oligomer was visualized by cryo-EM analysis, providing a structural snapshot of activated ClpC unfolding a protein substrate. Finally, drug susceptibility and degradation assays performed in mycobacteria demonstrate in vivo activity of BacPROTACs, allowing selective targeting of endogenous proteins via fusion to an established degron. In addition to guiding antibiotic discovery, the BacPROTAC technology presents a versatile research tool enabling the inducible degradation of bacterial proteins.

12 April 2019 in Science
Verified
Journal Article
Closed access
PBPierre Buscaill
Pierre Buscaill
BCBalakumaran Chandrasekar
Balakumaran Chandrasekar
NSNattapong Sanguankiattichai
Nattapong Sanguankiattichai
JKJiorgos Kourelis
Jiorgos Kourelis
FKFarnusch Kaschani
Farnusch Kaschani
RHRenier Van der Hoorn
Renier Van der Hoorn
Glycosylation goes back and forth: Plants produce receptors that recognize fragments of microbial flagellin, thus monitoring for infection by bacteria. Buscaill et al. studied how a flagellin fragment is made accessible for recognition by host glycosidases, which degrade the glycosylations shielding the peptide that triggers the immune response. The pathogen, in turn, evades detection by altering flagellin glycosylation and inhibiting the host glycosidase. This aspect of plant defense against infection plays out in the apoplast, the extracellular space within plant tissues. Science , this issue p. eaav0748

22 July 2008 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
ANAndrea Nören‐Müller
Andrea Nören‐Müller
WWWolfram Wilk
Wolfram Wilk
KSKrishna Saxena
Krishna Saxena
HSHarald Schwalbe
Harald Schwalbe
MKMarkus Kaiser
Markus Kaiser
HWHerbert Waldmann
Herbert Waldmann

21 April 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JCJérôme Clerc
Jérôme Clerc
MGMichael Groll
Michael Groll
DIDamir J. Illich
Damir J. Illich
ABAndré S. Bachmann
André S. Bachmann
RHRobert Huber
Robert Huber
MKMarkus Kaiser
Markus Kaiser
Syrbactins, a family of natural products belonging either to the syringolin or glidobactin class, are highly potent proteasome inhibitors. Although sharing similar structural features, they differ in their macrocyclic lactam core structure and exocyclic side chain. These structural variations critically influence inhibitory potency and proteasome subsite selectivity. Here, we describe the total synthesis of syringolin A and B, which together with enzyme kinetic and structural studies, allowed us to elucidate the structural determinants underlying the proteasomal subsite selectivity and binding affinity of syrbactins. These findings were used successfully in the rational design and synthesis of a syringolin A-based lipophilic derivative, which proved to be the most potent syrbactin-based proteasome inhibitor described so far. With a K i ′ of 8.65 ± 1.13 nM for the chymotryptic activity, this syringolin A derivative displays a 100-fold higher potency than the parent compound syringolin A. In light of the medicinal relevance of proteasome inhibitors as anticancer compounds, the present findings may assist in the rational design and development of syrbactin-based chemotherapeutics.